IL6 and cancer: As “a human inflammation model for cancer development” MPN are characterized by increase of serum inflammatory mediators (e.g., CRP, IL‐6, IL‐8, TNF‐α, and Th2 cytokines), clinical similarities with systemic inflammatory conditions (e.g., fatigue, fever, vasomotor symptoms, thrombocytosis, anemia, and spleen enlargement) and post‐inflammatory stigmata such as BM fibrosis.3, 8, 9